OR WAIT null SECS
September 26, 2024
Bolstered by a pilot program launched by the Biden administration, ReciBioPharm’s chief scientific officer, Aaron Cowley, discusses ongoing progress in developing continuous manufacturing for mRNA.
August 22, 2024
Vernal Biosciences’ CEO and founder, Christian Cobaugh, discusses the outsourcing landscape for mRNA production.
May 24, 2024
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
May 07, 2024
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.
April 30, 2024
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
April 16, 2024
The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.
April 11, 2024
Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.
March 01, 2024
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 02, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
December 03, 2023
Collaboration is a key component to achieving long-term success with genetic medicines.